June 26, 2025
ACHP submitted comments to CMS on its Draft Guidance for the third cycle of the Medicare Drug Price Negotiation Program, applicable to Initial Price Applicability Year (IPAY) 2028. ACHP strongly supports the inclusion of Medicare Part B drugs and the renegotiation of previously selected drugs from 2026 and 2027. In its recommendations, ACHP urges CMS to close product-hopping loopholes, ensure smooth implementation, apply Maximum Fair Price consistently across Medicare Advantage and require full transparency from manufacturers to protect patients and strengthen the Medicare program.
New from ACHP:
- ACHP Statement on Budget Reconciliation Bill
- ACHP Recommendations on Prescription Drug Machine-Readable File Requirement in Coverage Final Rule
- ACHP Opposes Senate Reconciliation Bill That Threatens Coverage for Millions
- ACHP Recommendations to Strengthen CMS Drug Price Negotiation Guidance for 2028
- GLP-1s Are Not A Silver Bullet
- Local Health Plans Meet Community Needs with Affordable, Accessible Vaccines
